Glenmark Pharmaceuticals Ltd
GLENMARKBSE 532296PharmaceuticalsMkt cap ₹65,936 Cr
Whole group, including subsidiaries — the figures companies headline.
Revenue · Q1 FY27
₹4,018 Cr
YoY +23.1%QoQ +6.6%
Net profit · Q1 FY27
₹483 Cr
YoY +928.0%QoQ +60.2%
Net margin · Q1 FY27
12.0%
+10.6 pts vs Q1 FY26
Net profit · FY26
₹1,362 Cr
YoY +30.1%
Quarterly results
| ₹ Cr | Q1 FY27 Apr–Jun 2026 | Q4 FY26 Jan–Mar 2026 | Q3 FY26 Oct–Dec 2025 | Q2 FY26 Jul–Sep 2025 | Q1 FY26 Apr–Jun 2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | 4,018 | 3,771 | 3,901 | 6,047 | 3,264 | +23.1% |
| Other income | 65.76 | 189 | 44.47 | 201 | 26.44 | +148.7% |
| Total income | 4,084 | 3,960 | 3,945 | 6,248 | 3,291 | +24.1% |
| Profit before tax | 643 | 388 | 534 | 967 | 95.58 | +573.1% |
| Tax | 161 | 86.45 | 131 | 357 | 48.60 | +230.4% |
| Net profit | 483 | 301 | 403 | 610 | 46.97 | +928.0% |
| Net margin | 12.0% | 8.0% | 10.3% | 10.1% | 1.4% |
Annual results
| ₹ Cr | FY26 Apr 2025–Mar 2026 | FY25 Apr 2024–Mar 2025 | FY24 Apr 2023–Mar 2024 | FY23 Apr 2022–Mar 2023 | FY22 Apr 2021–Mar 2022 | YoY |
|---|---|---|---|---|---|---|
| Revenue | 16,983 | 13,322 | 11,813 | 12,990 | 12,305 | +27.5% |
| Other income | 461 | 114 | 840 | 317 | 167 | +305.0% |
| Total income | 17,443 | 13,435 | 12,653 | 13,307 | 12,472 | +29.8% |
| Profit before tax | 1,985 | 1,399 | 36.49 | 868 | 1,441 | +41.8% |
| Tax | 623 | 352 | 1,867 | 491 | 448 | +76.9% |
| Net profit | 1,362 | 1,047 | -1,434 | 377 | 994 | +30.1% |
| Net margin | 8.0% | 7.9% | -12.1% | 2.9% | 8.1% |
BIC's take
We haven't covered Glenmark Pharmaceuticals Ltd yet. Browse our sector reports →
Source: BSE filings · Data as of 2 Oct 2026, 5:08 pm IST· ₹ crore unless stated. Covers BSE 500 companies only. Consolidated figures include subsidiaries; standalone is the parent company alone. Growth is shown only against a positive base. Not investment advice — check the company's full filing before acting.